PRAX241115C65000
- 6.28
- 0.000.00%
Praxis Precision Medicines Newsroom
Praxis Precision Medicines to Showcase Updates From Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
Praxis Solutions Welcomes Andre Hatibi as Senior Vice President of Business Development
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Piper Sandler Gives a Buy Rating to Praxis Precision Medicines (PRAX)
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $114 to $120
Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Praxis Precision Medicines: Strong Buy Rating Amid Potential Upside and Robust Pipeline Despite Operational Challenges
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $120 Price Target
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $114 to $170
Praxis Precision Medicine Analyst Ratings
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Promising Prospects and Financial Stability: Ritu Baral's Buy Recommendation for Praxis Precision Medicines
Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript Summary
Praxis Precision Medicines Q3 Net Loss Widens, Collaboration Revenue Falls; Shares Drop Pre-Bell
Optimistic Buy Rating for Praxis Precision Medicines Amid Strategic Pipeline Advancements and Long-term Growth Potential
Praxis Precision Medicines | 10-Q: Q3 2024 Earnings Report
Praxis Precision Medicines | 8-K: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Praxis Precision Medicines GAAP EPS of -$2.75 Misses by $0.76, Revenue of $0.3M In-line
Express News | Praxis Precision Medicines: Maintains Runway Into 2027